In a global Phase 3 colorectal cancer study, Precision's North American team turned a focused site management engagement into a pivotal contribution. When enrollment stalled after activation, the team built a prescreening tracker from scratch, identified a hemoglobin threshold that was systematically excluding eligible patients, and worked alongside the sponsor to amend the protocol.